- Home
- EDRY vs YARW Comparison
EDRY vs YARW Comparison
Compare EDRY & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDRY | YARW |
|---|---|---|
| Founded | 2018 | 2021 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.6M | 154.5M |
| IPO Year | 2018 | 2017 |
Fundamental Metrics
Financial Performance| Metric | EDRY | YARW |
|---|---|---|
| Price | $43.71 | $20.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $45.33 | ★ $57.00 |
| AVG Volume (30 Days) | 99.9K | ★ 114.2K |
| Earning Date | 11-12-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $40.95 | N/A |
| Revenue Next Year | $8.53 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.09 | $18.05 |
| 52 Week High | $73.07 | $44.28 |
Technical Indicators
Market Signals| Indicator | EDRY | YARW |
|---|---|---|
| Relative Strength Index (RSI) | 39.99 | 43.10 |
| Support Level | $42.00 | $18.05 |
| Resistance Level | $53.93 | $20.49 |
| Average True Range (ATR) | 3.47 | 1.38 |
| MACD | -0.48 | 0.52 |
| Stochastic Oscillator | 13.57 | 85.94 |
Price Performance
Historical ComparisonAbout EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About YARW Yarrow Bioscience Inc. Common Stock
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.